Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Trial Profile

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Belinostat (Primary) ; Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Rituximab (Primary) ; Filgrastim; Glutamine; Pyridoxine; Pyridoxine
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 03 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 11 Mar 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top